KRTX News and Press, Karuna Therapeutics Inc. From 12/23/19

The FDA's approval of Intra-Cellular Therapies' ( ITCI +191.6% ) schizophrenia drug bodes well for other companies with therapies for the central nervous system, writes Stifel analyst Paul Matteis. More news on: Intra-Cellular Therapies, Inc., Sage Therapeutics, Inc., ACADIA Pharmaceutic...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks, and our single stock focus. If you are interested in listening to Stocks To Watc...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Noteworthy events during the week of December 22 - 28 for healthcare investors. More news on: Change Healthcare Inc., Brickell Biotech, Inc., Adaptive Biotechnologies Corporation, Healthcare stocks news, , Read more ...

Christmas came early this year for anyone holding shares of these three biotech stocks. Each one produced eye-popping gains in 2019, but investors need to know if they can keep climbing in 2020 and beyond. Data source: Yahoo! Finance. While the short answer's "yes," there are some importa...

Aimmune Therapeutics (NASDAQ: AIMT ) initiated with Neutral rating and $33 (4% upside) price target at H.C. Wainwright. More news on: Aimmune Therapeutics, Inc., Ampio Pharmaceuticals, Inc., Apellis Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more ...

Biotech Pulse Biotechs finally have a gust of wind in their sails. In a space of 2 months, biotechs have gone from recording yearly lows in early October, to recording 2019 highs. The 25% surge has been a result of a relatively less threatening regulatory environment and a strengthening of...

This year was another crucial one for biotech thanks in large part to initial public offerings (IPOs), merger and acquisition (M&A) activity and niche therapeutic areas garnering attention. During the year, while the number of IPOs slowed in comparison to last year, some of the largest M...

The following slide deck was published by Karuna Therapeutics, Inc. in conjunction with this Read more ...

Karuna Therapeutics ( KRTX ) announced that it had achieved positive results from its phase 2 study using KarXT to treat acute psychosis in patients with schizophrenia. There was a substantial improvement achieved in the primary endpoint of the study. This was not only an important finding...